A proprietary strain of omega-3 fatty acid extract from the photoautotrophic microalgae Nannochloropsis that has been clinically confirmed to decrease remnant cholesterol by up to 25%.
Derived from triple-patented technology, AlmegaPL® is the first and only commercially available micro algae derived photosynthetic source of long-chain omega fatty acids available for human consumption. With a laser focus on environmental sustainability and overcoming omega-3 supply chain concerns, AlmegaPL® is suitable for a range of products, from nutraceuticals and functional foods to beverages and animal nutrition products. Read the full announcement here.
“This new opportunity marks a significant milestone in the omega-3industry, allowing SourceOne to offer our valued customers substantial differentiation through patented and clinically proven AlmegaPL® solutions across abroad range of product applications.” Jesse Lopez, CEO and Founder of SourceOne
AlmegaPL® has significant and valuable regulatory clearance, being listed as an NDI in the United States by the FDA and as a medicine in Australia by the TGA.
AlmegaPL® is the only phototrophic marine algae source of omega-3 that is grown and produced at an industrial scale in one of the largest algae farming facilities in the world.
Aside from valuable omega-3 essential fatty acids, AlmegaPL® also contains the following antioxidants that provide health benefits and protect the omega-3 against oxidation: glycolipids, phospholipids, chlorophyll A, lutein, omega-7, beta-carotene, and zeaxanthin.
AlmegaPL® is suitable for all consumers, including vegans, vegetarians, observers of kosher and halal.
AlmegaPL® is available as a raw material as well as bulk softgels for turnkey solutions.
AlmegaPL® decreases cholesterol in healthy adults: a double-blind, randomized placebo-controlled, three-month supplementation study.
Human Clinical Trial (120 healthy subjects)
Subjects were given 1 gram of AlmegaPL® per day standardized to 250 mg of EPA for three months.
Unmatched Results
AlmegaPL® significantly decreases total cholesterol (a) and "bad" (non-HDL) cholesterol (b) and remnant (VLDL) cholesterol, without increasing LDL cholesterol (d). This is a unique benefit associated to EPA-only formulations.
What does is mean?
AlmegaPL® is the only natural omega-3 source containing EPA-only that is available over-the-counter. Now, there is a plant based omega-3 supplement that has been clinically proven to decrease total- and remnant cholesterol, without increasing LDL-cholesterol, a side effect typically associated with fish oil and other DHA-containing supplements.
Please submit additional questions or comments, and a member of our team will promptly respond personally to your inquiry.
SourceOne's network of research and technology partners includes a new and exciting relationship with Qualitas Health (USA), recognized as a global pioneer in plant based omega-3 production. Qualitas Health currently holds patents for AlmegaPL® in 18 countries, including the US, and produces the only phototrophic marine algae source of omega-3 that is grown and produced at an industrial scale in one of the largest algae farming facilities in the world. Read the full announcement here.
Watch the following video from our brand partner, iwi life.